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The neuropathological hallmarks of Alzheimer’s disease
(AD) are neuronal and synaptic degeneration accompanied
by intracellular neurofibrillary tangles comprised hyper-
phosphorylated tau and extracellular plaques comprised am-
yloid-b (Ab1–42) protein [1]. The symptoms of AD develop
insidiously and progress slowly, most commonly starting
with memory impairment followed by deterioration in other
cognitive skills, resulting in progressive dementia with a
gradual loss of ability to perform activities of daily living.
An early diagnosis is crucial for counseling, for planning
treatment and care, and for advance directives. Scientifically,
the possibility of making an early (predementia) diagnosis is
essential for the clinical evaluation of novel, potentially
disease-modifying drugs against AD. The term “mild cogni-
tive impairment” (MCI) is often used to refer patients with
objective cognitive impairment and normal capabilities for
activities of daily living, who do not meet the criteria for de-
mentia [2–4]. MCI is a significant risk factor for dementia
and may in some cases represent the prodromal phase of
AD or other neurodegenerative disorders. Approximately
35% of MCI patients progress to AD dementia within a 3-
year follow-up with an annual conversion rate of 5%–10%
[5]. However, there are many causes of MCI, not all are
related to progressive neurodegenerative disorders. Thus,
diagnosing the underlying etiology is very challenging in
an individual patient with cognitive impairment, and there
is a need for more accurate diagnostic tests to identify
MCI patients in whom AD may be the underlying cause,
early in the course of the disease.
Consequently, international working groups have devel-
oped clinical criteria for the diagnosis of MCI because of
AD, which include the option to improve prognostic accu-
racy, with the use of biomarkers [2,6]. Currently, the most
validated biomarkers for early detection in clinical use
include markers of neuronal injury and of Ab1–42: medial
temporal lobe atrophy (as assessed on magnetic resonance
imaging [MRI]), a characteristic pattern of cerebral glucose
metabolism (as assessed on fluorodeoxyglucose positron
emission tomography [FDG-PET]), amyloid deposition in
the brain (as assessed by amyloid-PET), and lower levels of
Ab1–42 together with elevated levels of tau and phosphory-
lated tau (p-tau) in the cerebrospinal fluid (CSF).In the diagnostic criteria for MCI because of AD, devel-
oped by the National Institute on Aging and the Alzheimer’s
Association (NIA-AA), a positive Ab biomarker (either by
amyloid-PET or CSF) together with the presence of a
neuronal injury biomarker, such as medial temporal lobe at-
rophy or elevated levels of tau and p-tau in the CSF, indicates
that the MCI syndrome may be because of AD, whereas
negative Ab biomarkers suggest that MCI is unlikely
because of AD [2]. The international working group 2
criteria for prodromal AD are 1) the presence of episodic
memory decline of the hippocampal type as the leading clin-
ical symptom and 2) positive biomarker evidence from
either CSF or imaging that supports the presence of underly-
ing AD pathology [6].
Although brain imaging with MRI, FDG-PET, and am-
yloid PET often require advanced imaging analyses,
which may not be easily accessible everywhere, a lumbar
puncture (LP) may be done in many different clinical set-
tings and CSF samples can, if needed, easily be shipped to
a central laboratory for analysis. Numerous articles,
including large multicenter studies and meta-analyses
and systematic reviews (see Table 1), have confirmed
the predictive value of CSF biomarkers in patients with
MCI. However, there is a need to reach a consensus on
the application of CSF biomarkers in clinical practice
because it currently varies from country to country, and
even from site to site, and because early predementia diag-
nosis of AD is associated with unique clinical challenges
and ethical concerns [17,18].
The aim of this recommendation article was to provide
consensus recommendations on the clinical use of CSF bio-
markers in subjects with MCI using the Grading of Recom-
mendations, Assessment, Development, and Evaluation
(GRADE) method [19–21].
The present recommendations and the corresponding rec-
ommendations for the application of CSF biomarkers in
patients with dementia [22] were developed by Biomarkers
for AD and Parkinson’s disease (BIOMARKAPD), a project
supported by the EU Joint Program—Neurodegenerative
Disease Research (JPND) involving clinicians and re-
searchers from 19 countries with the aim to standardize
the assessment of established and new fluid biomarkers for
AD and PD.
Table 1
Meta-analyses and systematic reviews
Reference Year Type
Other
markers CSF marker
Timespan
searched
Number of
studies Comments
Olsson
et al. [7]
2016 Systematic
review and
meta-analysis
NFL
NSE
VLP-1
HFABP
Ab1–40
Ab1–38
sAPPa
sAPPb
Albumin
ratio
YKL-40/MCP-1
GFAP
Ab1–42 July 1984
to June
2014
131 A CSF signature of elevated tau
and p-tau and reduced Ab1–42
is consistently observed in
MCI patients who progress to
AD. The other investigated markers
need more research
Tau 151
P-tau 89
Mo
et al. [8]
2015 Systematic
review and
meta-analysis
Ab1–42 January
2004 to
October
2013
17 Only one of the studies reported
MCI to AD data
Ferreira
et al. [9]
2014 (October) Meta-analysis Ab1–42 January
1990 to
September
2013
12 The Ab1–42/p-tau ratio had
the highest capability to
predict conversion to AD
Tau
P-tau
Ritchie
et al. [10]
2014 Cochrane review Ab1–42,
CSF,
and
plasma
No restriction 14 CSF Ab1–42 levels cannot be
recommended in an MCI
population as a test for AD
Ferreira
et al. [11]
2014 (March) Systematic
review
Ab1–42 January
1990 to
September
2013
7 Systematic
reviews or
meta-analysis
and 26
primary
studies
Best performance for the
prediction of conversion to
AD was achieved with
combinations of two or
all three CSF markers
Tau
P-tau
Noel-Storr
et al. [12]
2013 Systematic
review
FDG-PET
PIB-PET
MRI
Ab1–42 2000 to
August
2011
37 Few large studies and
variability in biomarker
assessment
van Rossum
et al. [13]
2010 Meta-analysis Ab1–42 2002–2009 7 The combination of Ab1–42
and tau was the best predictor
of conversion to AD
Tau 11
P-tau 8
Schmand
et al. [14]
2010 Meta-analysis MRI MTL
atrophy
Ab1–42 January
2003 to
November
2008
14 CSF markers are abnormal
slightly earlier than brain
atrophy measured by MRI
Tau 14
P-tau 14
Mitchell [15] 2009 Meta-analysis P-tau Until
February
2009
6 P-tau was modestly successful
in predicting progression
to dementia
Diniz
et al. [16]
2008 Systematic
review and
meta-analysis
Ab1–42 January
1999 to
April 2007
4 MCI patients with high tau
and p-tau and low Ab1–42 at
baseline are more likely
to convert to AD
Tau 5
P-tau 3
Abbreviations: CSF, cerebrospinal fluid; NFL, neurofilament light protein; Ab1–42, amyloid-b 1-42; NSE, neuron-specific enolase; p-tau, phosphorylated tau;
VLP-1, visinin-like protein; HFABP, heart fatty acid–binding protein; MCI, mild cognitive impairment; Ab1–40, amyloid b1–40; AD, Alzheimer’s disease;
Ab1–38, amyloid b1–38; sAPPa, soluble amyloid precursor protein a fragment; sAPPb, soluble amyloid precursor protein b fragment; MCP-1, monocyte chemo-
tactic protein 1 (also called YKL-40); GFAP, glial fibrillary acidic protein; FDG, fluorodeoxyglucose; PET, positron emission tomography; PIB, Pittsburgh
compound B; MRI, magnetic resonance imaging; MTL, medial temporal lobe atrophy.
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2.1. Working group composition and group process
For a detailed description of our application of the
GRADE process, we refer to our recommendation article
on dementia [22] and to previous methodological GRADE
articles [19–21].The working group for this guideline comprised 28 inter-
national members, including neurologists, psychiatrists, spe-
cialists in clinical chemistry, and epidemiologists. The
evidence gathering, evaluation, and synthesis were led by
five experts (MB, PJV, RH, S-KH, and AHS) and the devel-
opment of clinical recommendations was chaired by GW.
All recommendations were developed by consensus
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face-to-face meetings; between the meetings, the progress
was evaluated by e-mail. The face-to-face meetings were
used to 1) establish a modified GRADE method for the
development of recommendations for a diagnostic interven-
tion; 2) to identify the most important clinical questions and
outcomes; 3) to establish the methods for literature search
and guidelines for evaluating the evidence; 4) to reach a
consensus on each of the steps in GRADE, including the
final recommendations; and 5) reach a consensus on opera-
tional aspects regarding the implementation of CSF bio-
markers in clinical practice. The final draft of the
manuscript was revised and commented on by all the coau-
thors.
First, the group applied the PICO format to select clinical
questions on the use of CSF biomarkers taking into account
the population (P), diagnostic strategy or intervention (I),
comparison strategy (C), and patient outcomes (O).
For each clinical question defined in the PICO process, a
MEDLINE search was conducted to identify relevant meta-
analyses, systematic reviews, and research articles to address
this question.Morearticleswere thenadded fromother sources
including reference lists fromarticles in original search results.
MEDLINE search strings were as follows:
(Cerebrospinal fluid OR CSF) AND diagnos* AND (mild
cognitive impairment OR MCI OR prodromal AD) AND
(tau OR beta amyloid OR abeta) AND (sensitivity OR
specificity)
(Cerebrospinal fluid OR CSF) AND diagnos* AND (mild
cognitive impairment OR MCI OR prodromal AD) AND
(tau OR beta amyloid OR abeta) AND (MRI OR PET OR
SPECT)
(Cerebrospinal fluid OR CSF) AND diagnos* AND (mild
cognitive impairment OR MCI OR prodromal AD) AND
(tau OR beta amyloid OR abeta) AND added value.
After searching for evidence and identifying the relevant
clinical questions, the GRADE level for each article that pro-
vided data to one of the clinical questions was assessed for
each relevant outcome.
To ensure the consistency of the grading system, a grading
algorithm was used as an aid. The article was assigned an up-
graded level of quality for the patient population if
 it originated consecutively from a memory clinic, with
at least 20 MCI cases;
 the diagnostic criteria both at the MCI stage and at
follow-up were well described;
 the baseline and follow-up diagnoses were based on
clinical specialist consensus according to well-
defined criteria and blinded to the CSF result;
 detailed clinical and demographic data with clinical
follow-up for at least 1 year;
 a detailed description of the analytical method used in
a single laboratory with reported cut-off values and a
high success rate; and autopsy-confirmed diagnosis.
The grading of each research article was added to the ev-
idence tables. The overall quality of evidence for each clin-
ical question was discussed in the meetings. Once the
consensus decision was reached, the quality of the evidence
for each relevant outcomewas graded as “high,” “moderate,”
“low,” or “very low.” Recommendations for questions, for
which there was no available evidence, were developed after
focused discussions in the working group at face-to-face
meetings.2.2. Operational aspects
In addition, the group discussed operational aspects,
namely, 1) the possible complications of LP, 2) the interpre-
tation of laboratory results, and 3) counseling of patients
before and after the biomarkers analysis. Finally, based on
the evidence and group discussion, a decision tree of using
CSF biomarkers in the clinical assessment of MCI patients
was drawn (Fig. 1).3. Results
3.1. Steps 1–2: PICO definition of clinical questions
The working group identified six clinical questions to be
addressed using the PICO method. The clinical questions
were scored and ranked by importance, and the results
are shown in Table 2. The highest rank was given to
questions identifying or excluding AD (defined as a patho-
logically confirmed diagnosis) as the cause of MCI
and predicting conversion to AD dementia (defined as an
AD diagnosis based on clinical criteria) within 3 years fol-
lowed by the prediction of functional or cognitive decline
(even without dementia). The three other clinical questions
on changing disease management, improving patient
well-being, and reducing health care costs were discussed
at length during the workshop. Because of the limited
evidence available, a large number of the members
ranked “improving patient well-being” as the most impor-
tant question, whereas a slight majority ranked it the least
important.3.2. Step 3–4: Identifying the evidence and rating the
quality
Table 1 lists all the identified systematic reviews and
meta-analyses.
The first search for the predictive value of CSF bio-
markers produced 137 articles and, in the end, 23 articles
fulfilled the inclusion and exclusion criteria. The search
for comparisons between CSF biomarkers and imaging
biomarkers produced 117 articles, and 20 articles were
included in the final data analysis. The search for the
added value of CSF biomarkers produced 348 articles,
of which 16 met the inclusion and exclusion criteria.
Fig. 1. Decision tree on the recommended use of the cerebrospinal fluid (CSF) biomarkers in diagnostic workup on patients with clinical diagnosis of mild
cognitive impairment. *Diagnosis based on medical history, clinical and basic neuropsychological examination, and basic neuroimaging. MCI, mild cognitive
impairment; MRI, magnetic resonance imaging;MTA, medial temporal lobe atrophy; AD, Alzheimer’s disease; FDG, fluorodeoxyglucose; PET, positron-emis-
sion tomography; Ab, amyloid-b; P-tau, phosphorylated tau.
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subsection. The information on the quality of evidence
presented in the articles identified in each subsection is
summarized in the Supplementary Tables 1–3.
No evidence tables were produced for clinical
questions 5–6 concerning the effects on patient well-
being and health economy, as during the search process,
it was evident that there was very little or no evidence
available.Table 2
The clinical questions and their rank scores in order of importance based on
workshop discussions (rank 1: most important)
Clinical questions: in patients with MCI, will
CSF biomarkers (alone or in combination)
compared with (A) clinical measures alone
and/or (B) other imaging biomarkers. Rank
1.. identify or exclude AD as the cause of
MCI?
1
2.. predict conversion to AD dementia
within 3 years?
1
3.. predict functional or cognitive decline? 2
4.. change disease management? 3
5.. improve patient well-being? 3
6.. reduce health care costs? 4
Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; MCI,
mild cognitive impairment.3.3. Steps 5–7: Rating the quality of evidence for each
clinical question
The Supplementary Tables 1–3 show the articles
included in the evidence for clinical questions 1–3.
When possible, the number of cases with each possible pa-
tient outcome in the test was calculated. Using the prede-
fined grading algorithm, each article was given a GRADE
level of “high,” “moderate,” “low,” or “very low” for each
clinical question. There was no evidence for the diag-
nostic value of CSF biomarkers in identifying AD pathol-
ogy as the cause of MCI, as there were no studies with CSF
AD biomarkers available with follow-up to neuropatho-
logical confirmation of the diagnosis. For the question
on predicting functional decline or progression to AD-
type dementia diagnosis during a 3-year follow-up, the
overall quality of the evidence was in terms of the
following:
 high and consistent for prediction by CSF alone;
 high and consistent for added value of CSF over clin-
ical measures alone; and
 conflicting and rated as low quality for added value
over other hypometabolism on FDG-PET and hippo-
campal atrophy on MRI. There was only one high-
quality article comparing diagnostic accuracy of CSF
biomarkers and amyloid-PET imaging in MCI,
Table 3
Final recommendations and recommendation strengths
Clinical question: in patients with
MCI, will CSF biomarkers as
compared with (A) clinical measures
alone and/or (B) other biomarkers.
a) Compared with clinical measures alone b) Compared with other biomarkers
Direction of
recommendation
Strength of
recommendation
Direction of
recommendation
Strength of
recommendation
1.. identify or exclude AD as
the cause of MCI?
NA NA NA
2.. predict functional or cognitive
decline?
Yes Strong Hippocampal
atrophy: yes
FDG-PET: no
Amyloid-PET: no
Hippocampal atrophy:
weak
FDG-PET: weak
Amyloid-PET: weak
3.. predict conversion to AD
dementia .3 years?
Yes Strong Hippocampal
atrophy: yes
FDG-PET: no
Amyloid-PET: no
Hippocampal atrophy:
weak
FDG-PET: weak
Amyloid-PET: weak
4.. change disease management? Yes Weak NA
5.. improve quality of life? Yes Weak NA
6.. reduce health care costs? No Weak NA
Abbreviations: MCI, mild cognitive impairment; CSF, cerebrospinal fluid; AD, Alzheimer’s disease; NA, not addressed; FDG-PET, fluorodeoxyglucose
positron-emission tomography.
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ficity than amyloid-PET in predicting progression to
AD dementia [23].3.4. Step 8: Developing the recommendations3.4.1. The role of CSF biomarkers in the diagnostic
evaluation of MCI patients
The final recommendations for each clinical question and
the strength of each recommendation, reflecting the strength
of the scientific evidence, are shown in Table 3. Therewas no
evidence for the diagnosis of AD pathology as the underly-
ing cause of MCI; so, no recommendation was given. The
working group recommended using the CSF biomarkers in
MCI as an add-on to clinical evaluation alone for predicting
functional decline or progression to AD dementia and, based
on the available evidence, the recommendation was strong.
However, in comparison with the outcome of using hippo-
campal atrophy as a biomarker, the working group issued a
weak recommendation to incorporate CSF biomarkers in
the diagnostic workup compared with hippocampal atrophy.
Because of insufficient evidence, the working group could
not recommend CSF biomarkers as an alternative to FDG-
PET or amyloid-PET in predicting future decline or conver-
sion. The working group recommended using CSF bio-
markers to inform future disease management, but the
strength of this recommendation was weak because of the
small amount of evidence. Clinical questions 5–6, concern-
ing the use of CSF biomarkers to improve patient well-being
and reduce health care costs, were discussed by the working
group, and recommendations were given based on expert
opinion as presented in Table 3.
In summary, the working group recommended that pa-
tients with mild cognitive symptoms should be offereddiagnostic evaluation to identify specific and potentially
reversible causes that require specific treatment and
follow-up. A summary of the operational recommendations
of clinical use of CSF biomarkers in clinical use is provided
in the decision tree (Fig. 1).3.4.2. Complications of an LP
The CSF biomarker test for AD in MCI patients is not an
indispensable test, and the possible contraindications
(increased intracranial pressure, coagulopathy, and a skin
infection at the injection site) must be assessed carefully.
For example, the current use of anticoagulants is a contrain-
dication for LP, and the risk of stopping medication for LP
because of an AD biomarker test must be considered. Tran-
sient back pain and headache may be reported after LP [24].
The considerations in the multidisciplinary working group
concerning possible were described in the recommendation
article on dementia [22].
3.4.3. Counseling of patients before an LP
The working group agreed on the following recommen-
dations concerning information to be provided during coun-
seling before asking for consent to the LP in a patient with
MCI:
 CSF may help to identify rare conditions, such as neu-
roinflammatory or infectious diseases that can be
treated;
 CSF biomarkers may identify the risk of symptom pro-
gression and confirmAD as the cause of the symptoms:
with unknown biomarker status, the 3-year risk of pro-
gression to dementia is approximately 35%, with nega-
tive biomarkers it is 14%, and with positive AD
biomarkers it is 54% [25];
 in the case of positive AD biomarkers, a personal
follow-up plan will be offered and appropriate support
S.-K. Herukka et al. / Alzheimer’s & Dementia 13 (2017) 285-295 291will be initiated in the case of symptom progression. In
addition, such information may be important for per-
sonal planning; and
 in the case of negative AD biomarkers, an intensive
follow-up plan may not be necessary (if no additional
symptoms that may indicate a neurodegenerative disor-
der other thanAD present) and such informationmay be
important for personal planning and well-being.3.4.4. Interpretation of CSF biomarker results
The cut-off points for CSF Ab1–42, tau, and p-tau have
varied considerably between laboratories. In general, Euro-
pean laboratories have operated with cut-off points for
Ab1–42 that were too low, resulting in the underdiagnosis
of AD [26]. The BIOMARKAPD consortium has recently
developed recommendations for appropriate cut-off points
[26–28].
We recommend to use the same cut-off points regardless
of apolipoprotein E (APOE) genotype. Ab1–42 levels are
highly associated with APOE genotype and individuals car-
rying the APOE ε4 allele (a major susceptibility gene for
AD) may have low CSF Ab1–42 without the clinical symp-
toms of AD [29–32]. However, CSF Ab1–42 is strongly
associated with cortical Ab accumulation independent of
APOE genotype, and the association of APOE ε4 with low
CSF Ab1–42 simply reflects this association. Similarly,
although Ab decreases with age in the normal population,
this again reflects increasing amyloid accumulation in the
brain as seen with aging [33]. The strategy for interpreting
normal CSF biomarker results, conflicting CSF biomarker
results, and abnormal CSF biomarker results is shown in
the decision tree (Fig. 1).3.4.5. CSF biomarker results that are conflicting with other
AD biomarker results
In these cases, biomarkers as a whole may be less infor-
mative as to the cause and prognosis of the MCI syndrome.
However, even with negative biomarkers and conflicting
biomarkers, there is still a risk of progression to AD demen-
tia, albeit much smaller [25]. It is essential to interpret
biomarker results close to the cut-off points with care.
Analytical variation (often around 10%) in the biomarker
measurements may result in a fairly significant gray zone
within which it is impossible to tell whether the individual
patient is positive or negative for a certain biomarker [28].
In such cases, repeated testing and clinical evaluation should
be provided.
3.4.6. Counseling of patients with positive biomarkers after
CSF biomarker study—disclosure of results
The working group recommended that counseling is
offered to inform the patient with MCI what to do to stay
well for as long as possible (e.g., intervention to reduce
life style–related risk factors and offer multimodal training
[34]) and to provide a follow-up program to: offer continuous counseling and support,
 monitor the development of symptoms and functional
status,
 treat comorbidities,
 offer pharmaceutical treatment as early as possible;
and
 offer participation in intervention trials.3.4.7. Cost and availability
The considerations in the multidisciplinary working
group concerning cost and availability were described in
the recommendation article on dementia [22]. A routine clin-
ical CSF biomarker test is available in every hospital as the
CSF samples can be sent to outside laboratory for analysis of
Ab1–42, tau, and p-tau. The cost is relatively low [35,36], but
LP requires personnel with the appropriate training and
facilities. Routine LP might therefore raise logistical
issues of upscaling that must be addressed [37] in relation
to availability of other (imaging) biomarkers.4. Discussion
We aimed to produce recommendations for the clinical
application of CSFAD biomarkers in the diagnostic evalua-
tion of patients with MCI under the JPND BIOMARKAPD
program. Using the GRADE method, we systematically
searched the literature and reached a consensus on the rec-
ommendations for the clinical application of AD CSF bio-
markers among patients with cognitive impairment who do
not meet the criteria for dementia. In patients with MCI,
will CSF biomarkers, compared with clinical measures
alone and/or other imaging biomarkers, 1) identify or
exclude AD as the underlying cause of MCI and 2) predict
conversion to AD dementia within 3 years? These questions
were defined and ranked as the most important clinical ques-
tions by the multidisciplinary working group, before initi-
ating the search and evaluation of scientific literature. The
working group found high-quality evidence that supports
the use of CSF biomarkers alongside clinical measures to
predict cognitive decline and conversion to AD over a 3-
year follow-up period. However, when CSF biomarkers
were compared with various imaging biomarkers, the
amount of evidence was significantly lower, largely because
of limited number of studies, which were sometimes also
contradictory. We therefore could not recommend one AD
biomarker over another to predict cognitive decline and con-
version to AD. Based on expert opinion discussed at face-to-
face meetings, the working group also developed a decision
tree for the interpretation of results and recommended pre-
and post-biomarker counseling. There was little or no evi-
dence available for evaluation of the value of CSF bio-
markers in changing disease management, improving
patient well-being, or reducing health care costs.
From a clinical point of view, it is important to identify pa-
tients at risk for the development of AD-type dementia to
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tions. An increasing number of patients are referred to mem-
ory clinics with very mild symptoms that may be because of
AD, andmany of these patients request a thorough diagnostic
evaluation and information about their diagnosis, that is, the
cause of their symptoms. CSF and other AD biomarkers may
help to identify the subgroup of patients with MCI because of
AD, although with some uncertainty, and such patients may
need intensified follow-up and intervention. Also, patients
with an early diagnosis ofMCI because of ADmay be offered
the possibility of participating in clinical trials with new
potentially disease-modifying drugs and in nonpharmacolog-
ical interventions. Without biomarkers, there is a risk of over-
diagnosing AD in MCI cases where progression to dementia
is unlikely. For patients with dementia, international guide-
lines recommend the use of CSF biomarkers and/or other
AD biomarkers to support the AD diagnosis [38–40].
However, for patients with mild impairment who do not
meet the clinical criteria for dementia, there are no clinical
guidelines concerning the utility of CSF biomarkers.
So far, the application of biomarkers in the clinical
routine is hampered by a lack of harmonization and stan-
dardization and by the varying access to biomarkers.
Furthermore, although an early diagnosis may pave the
way toward early treatment and support, there are also
ethical issues associated with establishing a very early diag-
nosis in an incurable disease.
There was strong evidence for the use CSF biomarkers in
addition to clinical measures when predicting functional or
cognitive decline or the conversion to AD dementia in pa-
tients with MCI. Notably, the available evidence relates to
the prediction of clinical outcome, not to predicting underly-
ing pathology, which is one of the major limitations dis-
cussed during the development of the present
recommendations. Although there are some articles avail-
able on the comparison between CSF biomarkers and neuro-
pathological results in dementia, there are no studies where
MCI patients with CSF and other biomarkers were followed
to a final clinical diagnosis and autopsy with a neuropatho-
logical confirmation of the diagnosis. Therefore, the work-
ing group could not give recommendation on the use of
CSF biomarkers for identifying the AD-type neuropa-
thology. However, the follow-up period of patients was rela-
tively long in many studies, which increases the reliability of
information concerning the conversion to clinical AD or re-
maining as stable MCI in the course of the disease. Further-
more, circumstantial evidence suggests that of the three
studied biomarkers, CSF Ab1–42 is associated with AD
pathology in the brain of subjects withMCI. CSFAb1–42 cor-
relates strongly with PET-amyloid deposition, and PET-
amyloid strongly correlates with brain amyloid, also in
subjects with MCI [23,27,41]. Thus, it is likely that CSF
Ab1–42 correlated with brain Ab in subjects with MCI.
Comparing the diagnostic performance, in patients with
MCI, of CSF biomarkers to other AD biomarkers, temporal
lobe atrophy on MRI, FDG-PET, or amyloid-PET, therewere fewer articles, and the results were conflicting. Espe-
cially in case of CSF tau and p-tau, there were very few
studies fulfilling the search criteria. Thus, the group was
not able to recommend one biomarker modality above
another and noted that more research studies with direct
comparison of the added value of CSF and imaging bio-
markers are needed. In the current clinical practice, the
availability of PET imaging in the close proximity or an
expert laboratory on CSF analysis near the treating clinician
may in reality play a role in selection of a biomarker used.
However, particularly in patients in whom LP with CSF
routine analysis is already indicated, the analysis of CSF
for AD biomarkers is an easily accessible study.
One study researched the cost-effectiveness of CSF bio-
markers in dementia [42]. Several aspects limited the gener-
alizability of that study. It tested the effect of CSF measures
alone on costs in relation with off-label treatment with done-
pezil in subjects with dementia. This is a highly unlikely sce-
nario for subjects with MCI as acetylcholinesterase
inhibitors are not recommended in MCI. Evidence from
the literature revealed that CSF AD biomarker information
most likely does not have a direct effect on health [43,44]
because no effective pharmacological treatment is
available in MCI [45–47]. Several studies revealed
positive, neutral, and negative reactions during interviews
after patients received a diagnosis of MCI, but these
reactions have not been tested after disclosure of AD as
the most likely cause of this syndrome [48–50]. Reactions
after disclosure of the MCI diagnosis included relief of not
having dementia, worrying if dementia because of AD will
develop over time, planning activities, and stress, and it is
likely that similar reaction will apply after disclosure of
CSF biomarker status in MCI. Concerns about
stigmatization have also been addressed [51]. These reac-
tions, however, regard the diagnosis of the MCI syndrome.
The strength of this article is the participation of a large in-
ternational multidisciplinary team. The work was based on a
systematic review of a vast amount of research evidence, and
the development of the recommendations was based on the
GRADE method and face-to-face consensus meetings.
Our literature searches highlighted the need for more
studies whereMCI patients have been followed until autopsy
and prospective studies where the diagnostic and prognostic
performance of the CSF biomarkers compared with other
biomarker modalities. A new international task force “Road-
map to the Biomarker-Based Diagnosis of Alzheimer’s Dis-
ease” aims to 1) identify the gaps of evidence to full clinical
validity of AD biomarkers (neuropsychology, CSF, and im-
aging) for the etiologic diagnosis of AD at theMCI stage and
2) prioritize them into a coherent and cost-effective road-
map, to form a strategic research agenda. As already pointed
out for CSF biomarkers in our recommendation, the road-
map initiative has revealed a relative lack of evidence con-
cerning prospective studies in patients with MCI on
clinical validity and clinical utility for most AD biomarkers
(Frisoni G., personal communication).
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the GRADE method to develop recommendations for the
application of CSF biomarkers in patients with MCI. The
working group identified the most important PICO questions
as: in patients with MCI, will CSF biomarkers, compared
with clinical measures alone, and/or other imaging bio-
markers identify or exclude AD as the cause of MCI and pre-
dict conversion to AD within 3 years? Based on currently
available evidence and focused face-to-face consensus meet-
ings, the working group recommended the use of CSF AD
biomarkers for the prediction of clinical progression or
conversion to AD dementia in patients with MCI with appro-
priate pre- and post-biomarker counseling. No recommenda-
tions could be given on the priority of CSF biomarkers
versus other potential AD biomarkers because of insufficient
or conflicting evidence. More studies are needed on the clin-
ical validity and utility of CSF and other biomarkers in pre-
dicting clinical progression to AD dementia in patients with
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1. Systematic review: The authors developed the rec-
ommendations for the clinical use of CSF biomarkers
in diagnostic evaluation of MCI patients based on
systematic review of literature and application of
the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) method.
2. Interpretation: Based on the published scientific evi-
dence and group discussions, the group recommends
the use of CSF biomarkers in predicting the func-
tional or cognitive decline or conversion to AD de-
mentia within 3 years. Furthermore, the group
recommends counseling both before and after the
biomarker evaluation.
3. Future directions: Studies with follow up from the
MCI stage of the disease to dementia and autopsy
are necessary to get direct evidence on whether or
not these biomarkers can identify AD pathology as
the underlying cause of MCI. Also, more studies
comparing different biomarker modalities within
the same patient populations are needed to compare
their performance in predicting AD dementia in
MCI patients.
S.-K. Herukka et al. / Alzheimer’s & Dementia 13 (2017) 285-295294References[1] Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet
2006;368:387–403.
[2] Albert MS, DeKosky ST, Dickson D, Dubois B, FeldmanHH, FoxNC,
et al. The diagnosis of mild cognitive impairment due to Alzheimer’s
disease: recommendations from the National Institute on Aging-Alz-
heimer’s Association workgroups on diagnostic guidelines for Alz-
heimer’s disease. Alzheimers Dement 2011;7:270–9.
[3] Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V,
Fratiglioni L. Mild cognitive impairment: a concept in evolution. J
Intern Med 2014;275:214–28.
[4] Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L,
Wahlund LO, et al. Mild cognitive impairment—beyond contro-
versies, towards a consensus: report of the International Working
Group on Mild Cognitive Impairment. J Intern Med 2004;256:240–6.
[5] Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive
impairment to dementia—meta-analysis of 41 robust inception cohort
studies. Acta Psychiatr Scand 2009;119:252–65.
[6] Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL,
Blennow K, et al. Advancing research diagnostic criteria for Alz-
heimer’s disease: the IWG-2 criteria. Lancet Neurol 2014;13:614–29.
[7] Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M,
et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s dis-
ease: a systematic review and meta-analysis. Lancet Neurol 2016;
15:673–84.
[8] Mo JA, Lim JH, Sul AR, Lee M, Youn YC, Kim HJ. Cerebrospinal
fluid beta-amyloid1-42 levels in the differential diagnosis of Alz-
heimer’s disease—systematic review and meta-analysis. PLoS One
2015;10:e0116802.
[9] Ferreira D, Rivero-Santana A, Perestelo-Perez L, Westman E,
Wahlund LO, Sarria A, et al. Improving CSF biomarkers’ performance
for predicting progression from mild cognitive impairment to Alz-
heimer’s disease by considering different confounding factors: a
meta-analysis. Front Aging Neurosci 2014;6:287.
[10] Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L,
Mason SE, et al. Plasma and cerebrospinal fluid amyloid beta for the
diagnosis of Alzheimer’s disease dementia and other dementias in peo-
ple with mild cognitive impairment (MCI). Cochrane Database Syst
Rev 2014;(6):CD008782.
[11] Ferreira L, Ferreira Santos-Galduroz R, Ferri CP, Fernandes
Galduroz JC. Rate of cognitive decline in relation to sex after 60
years-of-age: a systematic review. Geriatr Gerontol Int 2014;
14:23–31.
[12] Noel-Storr AH, Flicker L, Ritchie CW, Nguyen GH, Gupta T, Wood P,
et al. Systematic review of the body of evidence for the use of bio-
markers in the diagnosis of dementia. Alzheimers Dement 2013;
9:e96–105.
[13] van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors
for conversion from mild cognitive impairment to Alzheimer-type de-
mentia: implications for trial design. J Alzheimers Dis 2010;
20:881–91.
[14] Schmand B, Huizenga HM, van Gool WA. Meta-analysis of CSF and
MRI biomarkers for detecting preclinical Alzheimer’s disease. Psy-
chol Med 2010;40:135–45.
[15] Mitchell AJ. CSF phosphorylated tau in the diagnosis and prognosis of
mild cognitive impairment and Alzheimer’s disease: a meta-analysis
of 51 studies. J Neurol Neurosurg Psychiatry 2009;80:966–75.
[16] Diniz BS, Pinto Junior JA, Forlenza OV. Do CSF total tau, phosphor-
ylated tau, and beta-amyloid 42 help to predict progression of mild
cognitive impairment to Alzheimer’s disease? A systematic review
and meta-analysis of the literature. World J Biol Psychiatry 2008;
9:172–82.
[17] BocchettaM, Galluzzi S, Kehoe PG, Aguera E, Bernabei R, Bullock R,
et al. The use of biomarkers for the etiologic diagnosis of MCI in Eu-
rope: an EADC survey. Alzheimers Dement 2015;11:195–206.e1.[18] Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Per-
ret-Liaudet A, et al. The clinical use of cerebrospinal fluid biomarker
testing for Alzheimer’s disease diagnosis: a consensus paper from the
Alzheimer’s Biomarkers Standardization Initiative. Alzheimers De-
ment 2014;10:808–17.
[19] Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R,
Vist GE, et al. Grading quality of evidence and strength of recommen-
dations for diagnostic tests and strategies. BMJ 2008;336:1106–10.
[20] Brozek JL, Akl EA, Jaeschke R, LangDM, Bossuyt P, Glasziou P, et al.
Grading quality of evidence and strength of recommendations in clin-
ical practice guidelines: Part 2 of 3. The GRADE approach to grading
quality of evidence about diagnostic tests and strategies. Allergy 2009;
64:1109–16.
[21] Leone MA, Brainin M, Boon P, Pugliatti M, Keindl M,
Bassetti CLEuropean Federation of Neurological Societies. Guidance
for the preparation of neurological management guidelines by EFNS
scientific task forces—revised recommendations 2012. Eur J Neurol
2013;20:410–9.
[22] Simonsen AH, Herukka S-K, Andreasen N, Baldeiras I, Bjerke M,
Blennow K, et al. Recommendations for CSF AD biomarkers in the
diagnostic evaluation of dementia. Alzheimers Dement 2016. In press.
[23] Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM,
et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alz-
heimer’s disease. Ann Clin Transl Neurol 2014;1:534–43.
[24] Duits FH, Martinez-Lage P, Paquet C, Engelborghs S, Lleo A,
Hausner L, et al. Performance and complications of lumbar puncture
in memory clinics: results of the multicenter lumbar puncture feasi-
bility study. Alzheimers Dement 2016;12:154–63.
[25] Vos SJ, Verhey F, Frolich L, Kornhuber J, Wiltfang J, Maier W, et al.
Prevalence and prognosis of Alzheimer’s disease at the mild cognitive
impairment stage. Brain 2015;138:1327–38.
[26] Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleo A,
Herukka SK, et al. Use of amyloid-PET to determine cutpoints for
CSF markers: a multicenter study. Neurology 2016;86:50–8.
[27] Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U,
Brooks DJ, et al. Accuracy of brain amyloid detection in clinical prac-
tice using cerebrospinal fluid beta-amyloid 42: a cross-validation study
against amyloid positron emission tomography. JAMA Neurol 2014;
71:1282–9.
[28] Rosen C, Farahmand B, Skillback T, Nagga K, Mattsson N,
Kilander L, et al. Benchmarking biomarker-based criteria for Alz-
heimer’s disease: data from the Swedish Dementia Registry, SveDem.
Alzheimers Dement 2015;11:1470–9.
[29] Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al.
High cerebrospinal fluid tau and low amyloid beta42 levels in the clin-
ical diagnosis of Alzheimer disease and relation to apolipoprotein E
genotype. Arch Neurol 1998;55:937–45.
[30] Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R,
et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects
at risk for Alzheimer’s disease: the effect of APOE epsilon4 allele.
Biol Psychiatry 2004;56:670–6.
[31] Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS,
Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alz-
heimer’s disease neuroimaging initiative subjects. Ann Neurol 2009;
65:403–13.
[32] Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM,
Trojanowski JQ, et al. Effect of apolipoprotein E on biomarkers of am-
yloid load and neuronal pathology in Alzheimer disease. Ann Neurol
2010;67:308–16.
[33] Mattsson N, Rosen E, HanssonO, AndreasenN, Parnetti L, JonssonM,
et al. Age and diagnostic performance of Alzheimer disease CSF bio-
markers. Neurology 2012;78:468–76.
[34] Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S,
Antikainen R, et al. A 2 year multidomain intervention of diet, exer-
cise, cognitive training, and vascular risk monitoring versus control
to prevent cognitive decline in at-risk elderly people (FINGER): a
randomised controlled trial. Lancet 2015;385:2255–63.
S.-K. Herukka et al. / Alzheimer’s & Dementia 13 (2017) 285-295 295[35] Silverman DH, Cummings JL, Small GW, Gambhir SS, Chen W,
Czernin J, et al. Added clinical benefit of incorporating 2-deoxy-2-
[18F]fluoro-D-glucose with positron emission tomography into the
clinical evaluation of patients with cognitive impairment.Mol Imaging
Biol 2002;4:283–93.
[36] Moulin-Romsee G, Maes A, Silverman D, Mortelmans L, Van
Laere K. Cost-effectiveness of 18F-fluorodeoxyglucose positron emis-
sion tomography in the assessment of early dementia from a Belgian
and European perspective. Eur J Neurol 2005;12:254–63.
[37] Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, et al.
Health economic evaluation of treatments for Alzheimer’s disease:
impact of new diagnostic criteria. J Intern Med 2014;275:304–16.
[38] Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I,
et al. EFNS guidelines for the diagnosis and management of Alz-
heimer’s disease. Eur J Neurol 2010;17:1236–48.
[39] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr,
Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s dis-
ease: recommendations from the National Institute on Aging-Alz-
heimer’s Association workgroups on diagnostic guidelines for
Alzheimer’s disease. Alzheimers Dement 2011;7:263–9.
[40] Sorbi S, Hort J, Erkinjuntti T, Fladby T, Gainotti G, Gurvit H, et al.
EFNS-ENS guidelines on the diagnosis and management of disorders
associated with dementia. Eur J Neurol 2012;19:1159–79.
[41] Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A,
Palsson E, et al. Apolipoprotein E genotype and the diagnostic accu-
racy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA
Psychiatry 2014;71:1183–91.
[42] Valcarcel-Nazco C, Perestelo-Perez L,Molinuevo JL,Mar J, Castilla I,
Serrano-Aguilar P. Cost-effectiveness of the use of biomarkers incerebrospinal fluid for Alzheimer’s disease. J Alzheimers Dis 2014;
42:777–88.
[43] Bossuyt PMM, McCaffery K. Additional patient outcomes and path-
ways in evaluations of testing, in anonymous. Rockville MD: Medical
Tests—White Paper Series; 2009.
[44] Lee DW, Neumann PJ, Rizzo JA. Understanding the medical
and nonmedical value of diagnostic testing. Value Health 2010;
13:310–4.
[45] Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase in-
hibitors in mild cognitive impairment: a systematic review of rando-
mised trials. PLoS Med 2007;4:e338.
[46] Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive
impairment. Cochrane Database Syst Rev 2012;9:CD009132.
[47] Cooper C, Li R, Lyketsos C, Livingston G. Treatment for mild
cognitive impairment: systematic review. Br J Psychiatry 2013;
203:255–64.
[48] Frank L, Lloyd A, Flynn JA, Kleinman L, Matza LS, Margolis MK,
et al. Impact of cognitive impairment on mild dementia patients and
mild cognitive impairment patients and their informants. Int Psycho-
geriatr 2006;18:151–62.
[49] Lingler JH, Nightingale MC, Erlen JA, Kane AL, Reynolds CF 3rd,
Schulz R, et al. Making sense of mild cognitive impairment: a qualita-
tive exploration of the patient’s experience. Gerontologist 2006;
46:791–800.
[50] Joosten-Weyn Banningh L, Vernooij-Dassen M, Rikkert MO,
Teunisse JP. Mild cognitive impairment: coping with an uncertain la-
bel. Int J Geriatr Psychiatry 2008;23:148–54.
[51] Beard RL, Neary TM. Making sense of nonsense: experiences of mild
cognitive impairment. Sociol Health Illn 2013;35:130–46.
